It looks like ozone is going to be used in the treatment HIV in Italy. I asked this question once, but did not get an answer. Is OZON going to be involved with the purification of blood, or just medical equipment?
***
Tuesday October 21 8:15 AM EDT
Company Press Release
Medizone International To Move Forward With Human Clinical Trials
SALT LAKE CITY, Oct. 21 /PRNewswire -- Medizone International, Inc.
(OTC-Bulletin Board: MZEI.U) (''Medizone''), announced today it has
reached an agreement in principle to commence Phase I/II Human Clinical Trials at two prestigious Italian University sites using Medizone patented ''thin-film'' ozone technology. The clinical trials will test the safety, toxicity and efficacy of Medizone's patented ''thin-film'' ozone technology against the HIV virus in adults and children.
Medizone President and Chief Operating Officer, Milton G. Adair and the Company's Director of Research and Development, Gerard V. Sunnen, M.D., will travel to Italy the week of November 10, 1997 to finalize the details of the agreements with Dr. Mariano Franzini, Professor at the Universita of Pavia and President of the Italian Scientific Society for Oxygen-Ozone Therapy (''ISSOT'') who, as required by law, acts as an on-site coordinator. They will also meet with study site coordinators, Drs. Carlo Giaquinto and Umberto Tirelli. Dr. Giaquinto is a Professor at the Departimento of Pediatria, Universita di Padova, Padova, Italy, and Project Leader of the Pediatric AIDS Clinical Trial Group at Padova Universita Hospital. Dr. Tirelli serves as Chief, Division of Oncology and AIDS at the National Cancer Center, Aviano, Italy.
Once the final agreements are signed and the protocols approved, patient enrollment will begin. It is anticipated that the trials will commence during the first quarter of 1998.
Medizone's Chairman of the Board, Edwin Marshall stated, ''I'm extremely pleased with the energy and focus of our new management team. Moving forward with our research efforts is clearly the best use of our financial resources while providing us the opportunity to validate the patented Medizone ''thin- film'' technology.''
Medizone International, Inc., is a research and development stage
company engaged in the development of an ozone-based treatment for
diseases caused by lipid enveloped viruses, including Acquired Immune
Deficiency Syndrome (AIDS), Hepatitis B and Herpes; and in the
development of its patented technology for the decontamination of blood and blood products. For information call CTC, Inc., 937-434-2700 or Medizone International, Inc., 801-274-8400 or visit the company's website at medizoneint.com.
This press release contains certain forward-looking statements about the Company's goals and anticipated future performance. The industry in which the Company proposes to operate is dynamic and intensely competitive and there are many factors that could cause the
forward-looking statements contained herein not to occur or the timing
of their occurrence to be delayed. With the exception of historical
information, the matters discussed in this press release are forward-looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing
clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive
products and competitive environment, availability of raw materials and critical manufacturing equipment and facilities and other risks
identified in filings made with the Securities and Exchange Commission.
SOURCE Medizone International, Inc. |
